The UCL Technology Fund invests in world-class intellectual property from UCL researchers, primarily in the Physical and Life Sciences. Its strategy is to provide long-term capital and expertise to help commercialize and scale these technologies globally, supporting projects from proof-of-concept to market through licensing or spinout companies.
43% of their portfolio is in AI. Their most common stage is series-a (57% of deals). Average disclosed round size is $17.8M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
$259M
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Stanhope AI | Series A | $8M | Feb 2026 |
| GGaussion | Series A | $10.9M | Aug 2024 |
 Oriole Networks | Seed | $12.6M | Mar 2024 |
 Phasecraft | Series A | $15M | Aug 2023 |
 Tenpoint Therapeutics | Series A | $70M | Jul 2023 |
| CCarbon Re | Seed | $4.8M | Nov 2022 |
| EEchopoint Medical Ltd | Seed | $3.5M | Sep 2019 |
Top Co-Investors
AlbionVC2 shared
Parkwalk Advisors2 shared
XTX Ventures1 shared
Planet A1 shared
Clean Growth Fund1 shared
Cambridge Enterprise1 shared
Playground Global1 shared
London Co-Investment Fund (LCIF)1 shared
Frontline Ventures1 shared
Paladin Capital Group1 shared
Auxxo Female Catalyst Fund1 shared
MMC Ventures1 shared
AutoTech Ventures1 shared
BGF1 shared
British Patient Capital1 shared
F-Prime Capital1 shared
Sofinnova Partners1 shared
Qiming Venture Partners USA1 shared
Eight Roads Ventures1 shared
Last updated: 15 April 2026